Homotaurine

Homotaurine[1]
Skeletal formula
Ball-and-stick model
Names
IUPAC name
3-Aminopropane-1-sulfonic acid
Other names
Tramiprosate; Alzhemed; 3-APS
Identifiers
3687-18-1 YesY
ChEMBL ChEMBL149082 YesY
ChemSpider 1584 YesY
Jmol interactive 3D Image
KEGG D06202 YesY
PubChem 1646
Properties
C3H9NO3S
Molar mass 139.17 g·mol−1
Melting point 293 °C (559 °F; 566 K) (decomposition)
Hazards
R-phrases R36/37/38
S-phrases S26 S36
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
YesY verify (what is YesYN ?)
Infobox references


Homotaurine (3-amino-1-propanesulfonic acid (3-APS) or tramiprosate (INN)) is a synthetic organic compound. It is analogous to taurine, but with an extra carbon in its chain. It has GABAergic activity, apparently by mimicking GABA, which is it resembles.[2]

Homotaurine was investigated in a Phase III clinical trial as a potential treatment for Alzheimer's disease that did not show efficacy in its primary endpoints.[3] In preclinical studies it had been found to bind to soluble amyloid beta and inhibit the formation of neurotoxic aggregates.[3][4] Homotaurine has also shown anticonvulsant activities, reduction in skeletal muscle tonus, and hypothermic activity.[5]

Homotaurine has been reported as a GABA antagonist[2] as well as a GABA agonist.[6][5] In vitro studies have found that homotaurine is a GABAA partial agonist[7] as well as a GABAB receptor partial agonist with low efficacy, becoming an antagonist and a displacing full agonist of GABA or baclofen at this receptor.[8] In a study in rats, homotaurine reversed the catatonia induced by baclofen (the prototypical GABAB agonist),[9] and was able to produce analgesia via the GABAB receptor, an effect that was abolished when CGP 35348, a GABAB receptor antagonist was applied.[10][11]

One study in rats showed that homotaurine suppressed ethanol-stimulated dopamine release, as well as ethanol intake and preference in rats in a way similar to acamprosate.[12] Acamprosate, the N-acetyl derivative of homotaurine, was approved by the FDA in 2004 to treat alcohol dependence.[2]

References

  1. Homotaurine at Sigma-Aldrich
  2. 1 2 3 Lednicer D (2008). The Organic Chemistry of Drug Synthesis (7th ed.). Hoboken: John Wiley & Sons. p. 15. ISBN 978-0-470-18066-2.
  3. 1 2 Caltagirone C et al. The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review. Aging Clin Exp Res. 2012 Dec;24(6):580-7. PMID 22961121
  4. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D (2007). "Alzhemed: a potential treatment for Alzheimer's disease". Current Alzheimer Research 4 (4): 473–8. doi:10.2174/156720507781788882. PMID 17908052.
  5. 1 2 Oja SS and Kontro P. Taurine. Chapter 18 in Metabolism in the Nervous System, Ed. Lajtha ANS. Springer Science & Business Media, 2013. ISBN 9781468443677. Page 520
  6. Armen H. Tashjian and Ehrin J. Armstrong. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Edited by David E. Golan. Lippincott Williams & Wilkins, 2011 ISBN 9781451118056. Page 308
  7. Reyes-Haro D1, Cabrera-Ruíz E, Estrada-Mondragón A, Miledi R, Martínez-Torres A. "Modulation of GABA-A receptors of astrocytes and STC-1 cells by taurine structural analogs.". PMID 25119985.
  8. Giotti A, Luzzi S, Spagnesi S, Zilletti L. "Homotaurine: a GABAB antagonist in guinea-pig ileum.". PMID 6652358.
  9. Mehta AK1, Ticku MK. "Baclofen induces catatonia in rats.". PMID 2823166.
  10. Serrano MI1, Serrano JS, Fernández A, Asadi I, Serrano-Martino MC. "GABA(B) receptors and opioid mechanisms involved in homotaurine-induced analgesia.". PMID 9510095.
  11. Serrano MI1, Serrano JS, Asadi I, Fernández A, Serrano-Martino MC. "Role of K+ -channels in homotaurine-induced analgesia.". PMID 11468027.
  12. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. "Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.". PMID 11864639.
This article is issued from Wikipedia - version of the Saturday, March 12, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.